SK Telecom Co. has released a mobile app-based DNA testing service dubbed care8 DNA in partnership with its joint venture Invites Healthcare Co. and bio firm Macrogen Inc.
The subscription-based setting allows users to sign up for 29 types of genetic testing, such as for nicotine reliance and hair loss.
Users will receive DNA test kits at home, which they would send back to SK Telecom with their saliva for analysis.
Test results will be available on the care8 DNA app after two weeks.
According to SK Telecom, their DNA service, which costs 99,000 won for a one-year subscription, is more affordable than local direct-to-consumer (DTC) genetic tests.
The app also provides other services, such as personalized health coaching. More genetic tests would also be introduced.
SK Telecom, South Korea's largest mobile carrier, increased its investment in Israel-based startup Nano-X Imaging Ltd in June to boost its presence in the digital health care sector.
The global DTC genetic testing market is expected to increase to $6.4 billion in 2028 from $824 million in 2018.


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



